In a nutshell This study examined the impact of multi-drug resistant organisms in patients who had undergone stem cell treatment. The study concluded that patients colonized with multi-drug resistant organisms should be watched closely for infections after transplantation. Some background Stem cell transplantation is a treatment used in...
Read MoreCurrent disease status-First occurrence of the myeloma Posts on Medivizor
Treatment combinations for multiple myeloma patients with the 17p deletion
In a nutshell This study analyzed the results of 13 separate studies on treatment combinations for multiple myeloma patients with the 17p deletion. This study concluded that bortezomib-based primary and maintenance therapy improved outcomes in newly diagnosed patients with the 17p deletion. The combination...
Read MoreLooking for patients with refractory multiple myeloma to test blinatumomab after autologous stem cell transplantation
In a nutshell This phase 1 clinical trial will test the safety of blinatumomab (Blincyto) treatment after high-dose melphalan (Alkeran) and autologous stem cell transplant in patients with refractory (unresponsive to treatment) multiple myeloma. The primary outcome will be measured by the number of adverse (negative) effects. The trial is being...
Read MoreLooking for untreated multiple myeloma patients to test a first-line combination chemotherapy with stem cell transplantation
In a nutshell This phase 2 clinical trial will test the effectiveness of a high-dose BeEAM chemotherapy as a first-line treatment for multiple myeloma. The primary outcome will be measured by the response to the treatment. The details BeEAM is a combination chemotherapy containing 4 different drugs (bendamustine, etoposide, cytarabine, and...
Read MoreSearching for patients with high-risk smoldering multiple myeloma to test the effectiveness of an immunotherapy
In a nutshell This phase 2 clinical trial will test the effectiveness of isatuximab (SAR650984) in patients with high-risk smoldering multiple myeloma. The primary outcome will be measured by the overall response. This trial is being conducted at Mount Sinai Hospital and Memorial Sloan Kettering Cancer Center in New York, New York, as well as...
Read MoreTreatment options and combinations for multiple myeloma
In a nutshell The aim of this study was to review current treatment options and combinations for multiple myeloma. Some background Advances in first-line treatments have improved response and survival rates among multiple myeloma patients. In recent years immunotherapies and targeted therapies have become a major treatment option....
Read MoreLooking for patients with relapsed or refractory multiple myeloma to test the effectiveness of a combination chemotherapy prior to autologous stem cell transplantation
In a nutshell This phase 2 clinical trial will test the effectiveness of a combination of panobinostat (Farydak), gemcitabine (Gemzar), busulfan (Busulfex), and melphalan (Alkeran), and a stem cell transplant in treating multiple myeloma. The primary outcome will be measured by the time until the disease progresses. This trial is being conducted in...
Read MoreA look at frailty in elderly multiple myeloma patients
In a nutshell This study reviewed evidence on how to categorize older multiple myeloma patients. Some background Advances in treatment approaches have improved response rates and survival for multiple myeloma patients. These typically involve combining immunotherapies, such as lenalidomide (Revlimid), with proteasome inhibitors, such as bortezomib...
Read MoreCombining carfilzomib with cyclophosphamide and dexamethasone for newly diagnosed multiple myeloma
In a nutshell This study examined the safety of combining carfilzomib (Kyprolis), cyclophosphamide (Cytoxan), and dexamethasone Decadron) for multiple myeloma. Researchers reported early results on the safety and potential effectiveness of this treatment combination. Some background Advances in first-line treatments have improved response and...
Read MoreThree treatment combinations are as effective as four in previously untreated multiple myeloma
In a nutshell This study compared different treatment combinations for previously untreated multiple myeloma, including bortezomib (Velcade), dexamethasone (Ozurdex), cyclophosphamide (Cytoxan), and lenalidomide (Revlimid). This study concluded that a combination of all four therapies did not improve response rates beyond combinations of three...
Read More
